What does Intrexon Actobiotics do?

Intrexon Actobiotics is a research organisation in Nazareth-De Pinte. Public Limited, started on 3 July 2006, 1 establishment.

What is the address of Intrexon Actobiotics?

The registered office of Intrexon Actobiotics is located at Oudenaardseheerweg 129, 9810 Nazareth-De Pinte.

Is Intrexon Actobiotics still active?

Yes. According to the CBE (29 October 2026) Intrexon Actobiotics is active, legal situation “Normale toestand”, started on 3 July 2006.

Is Intrexon Actobiotics registered on Peppol?

Yes, Intrexon Actobiotics is registered on the Peppol network with ID 0208:0882251820.

What is the enterprise number of Intrexon Actobiotics?

The enterprise number of Intrexon Actobiotics is BE0882251820.

When was Intrexon Actobiotics founded?

Intrexon Actobiotics was founded on 3 July 2006.

Who are the directors of Intrexon Actobiotics?

According to the 2025 annual accounts, the directors of Intrexon Actobiotics are: Rutul Shah, Donald Lehr.

Is Intrexon Actobiotics a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 July 2006; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Intrexon Actobiotics make in 2025?

Intrexon Actobiotics recorded a loss after taxes of € 372,153 in financial year 2025.

What is the revenue of Intrexon Actobiotics?

As a small company, Intrexon Actobiotics is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -217,049.

How much does an employee at Intrexon Actobiotics earn?

The average wage cost per full-time employee at Intrexon Actobiotics was € 301,400 in 2024: staff costs of € 3.3 million for 10.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

Intrexon Actobiotics (Public Limited) - Nazareth-De Pinte

Dossier Intrexon Actobiotics, printed on 29 October 2026 from databakkes.be/en/0882251820/intrexon-actobiotics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

Intrexon Actobiotics from Nazareth-De Pinte, company number BE0882251820, closed financial year 2025 with a result of € -372,153 after tax. For that financial year Intrexon Actobiotics recorded a gross margin of € -217,049 and equity of € 8.6 million. Compared with financial year 2024, the result moved from € -2.5 million to € -372,153. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.

What it is worth Healthy

€ 8.6 million

▼ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -372,153

▲ 85 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 70,954

▲ 112% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -47.2 million.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 109,034

▲ 48% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 6,055,913 Revenue 2022: € 6,055,913 First fiscal year in the series	-	-	-
Gross margin	-	€ 2,029,768 Gross margin 2023: € 2,029,768 First fiscal year in the series	€ 609,502 Gross margin 2024: € 609,502 ▼ 70% vs 2023 (€ 2,029,768) Unfavourable step	€ -217,049 Gross margin 2025: € -217,049 ▼ € 826,551 vs 2024 (€ 609,502) Unfavourable step	▼ € 826,551
Profit after taxes	€ 766,025 Profit after taxes 2022: € 766,025 First fiscal year in the series	€ 206,403 Profit after taxes 2023: € 206,403 ▼ 73% vs 2022 (€ 766,025) Unfavourable step	€ -2,520,924 Profit after taxes 2024: € -2,520,924 ▼ € 2.7 million vs 2023 (€ 206,403) Unfavourable step	€ -372,153 Profit after taxes 2025: € -372,153 ▲ € 2.1 million vs 2024 (€ -2,520,924) Favourable step	▲ € 2.1 million
Equity	€ 11,278,683 Equity 2022: € 11,278,683 First fiscal year in the series	€ 11,485,086 Equity 2023: € 11,485,086 ▲ 2% vs 2022 (€ 11,278,683) Favourable step	€ 8,964,162 Equity 2024: € 8,964,162 ▼ 22% vs 2023 (€ 11,485,086) Unfavourable step	€ 8,592,009 Equity 2025: € 8,592,009 ▼ 4% vs 2024 (€ 8,964,162) Unfavourable step	▼ 4%
Total debts	€ 1,845,275 Total debts 2022: € 1,845,275 First fiscal year in the series	€ 1,313,566 Total debts 2023: € 1,313,566 ▼ 29% vs 2022 (€ 1,845,275) Favourable step	€ 813,546 Total debts 2024: € 813,546 ▼ 38% vs 2023 (€ 1,313,566) Favourable step	€ 170,895 Total debts 2025: € 170,895 ▼ 79% vs 2024 (€ 813,546) Favourable step	▼ 79%
Cash	€ 347,239 Cash 2022: € 347,239 First fiscal year in the series	€ 452,965 Cash 2023: € 452,965 ▲ 30% vs 2022 (€ 347,239) Favourable step	€ 33,547 Cash 2024: € 33,547 ▼ 93% vs 2023 (€ 452,965) Unfavourable step	€ 70,954 Cash 2025: € 70,954 ▲ 112% vs 2024 (€ 33,547) Favourable step	▲ 112%
Retained profit	€ -44,500,370 Retained profit 2022: € -44,500,370 First fiscal year in the series	€ -44,293,967 Retained profit 2023: € -44,293,967 Unchanged (€ -44,500,370) Favourable step	€ -46,814,891 Retained profit 2024: € -46,814,891 ▼ € 2.5 million vs 2023 (€ -44,293,967) Unfavourable step	€ -47,187,043 Retained profit 2025: € -47,187,043 ▼ € 372,153 vs 2024 (€ -46,814,891) Unfavourable step	▼ € 372,153
Balance sheet total	€ 13,123,957 Balance sheet total 2022: € 13,123,957 First fiscal year in the series	€ 12,798,652 Balance sheet total 2023: € 12,798,652 ▼ 2% vs 2022 (€ 13,123,957) Unchanged	€ 9,777,708 Balance sheet total 2024: € 9,777,708 ▼ 24% vs 2023 (€ 12,798,652) Unchanged	€ 8,762,904 Balance sheet total 2025: € 8,762,904 ▼ 10% vs 2024 (€ 9,777,708) Unchanged	▼ 10%
Employees (FTE)	18.6 Employees (FTE) 2022: 18.6 First fiscal year in the series	17.2 Employees (FTE) 2023: 17.2 ▼ 1.4 vs 2022 (18.6) Unchanged	10.9 Employees (FTE) 2024: 10.9 ▼ 6.3 vs 2023 (17.2) Unchanged	-

Key figures of Intrexon Actobiotics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Intrexon Actobiotics?

What happened at Intrexon Actobiotics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 Rutul Shah stepped down as director. NBB
Jul 3, 2026 New annual accounts for financial year 2025: loss of € 372,153. Source: NBB ↗
2026 Donald Lehr stepped down as director. NBB
2024 Rutul Shah became a director. NBB
2020 Donald Lehr became a director. NBB
Aug 10, 2006 New establishment in Nazareth-De Pinte. KBO
Jul 3, 2006 Start of the company according to the CBE. KBO

In short

From € 766,025 profit in 2022 to € 372,153 loss in 2025.

Paid € 6,872 in corporate taxes since 2022.

Best year ever: 2022, with € 766,025 profit.

On average € 55,900 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

ACTOBIO LABORATORIES BELGIUM 100%

The stake of ACTOBIO LABORATORIES BELGIUM comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Intrexon Actobiotics

The shares are held by ACTOBIO LABORATORIES BELGIUM (100%).

Directors

According to the 2025 annual accounts

Rutul Shah

Director

since 2024 · until 2030

Donald Lehr

Director

Also active at: ACTOBIO LABORATORIES BELGIUM

since 2020 · until 2026

Shareholders

ACTOBIO LABORATORIES BELGIUM

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Oudenaardseheerweg 129

9810 Nazareth-De Pinte

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 9 companies are registered at this address.

All companies at this address →

BOONEN L. CH.

€ 99,726 gross margin · 2024

RDW

€ 38,924 gross margin · 2025

ACCOUNTANCY EECHAUDT - MEERSMAN

ACTOBIO LABORATORIES BELGIUM same network

Vubiquity

€ 65,715 gross margin · 2025

+4 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0882.251.820
VAT number: BE 0882.251.820
Registered office: Oudenaardseheerweg 129, 9810 Nazareth-De Pinte
Names & denominations: Intrexon Actobiotics
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 3 July 2006
Peppol: Active · Active since 18 Sept 2024
Activities · NACE: Speur- en ontwikkelingswerk op biotechnologisch gebied

View on CBE Public ↗ Annual accounts (NBB) ↗